Global pharmaceutical giant Pfizer (NYSE: PFE) has commenced recruitment in Argentina for a Phase III clinical trial evaluating the efficacy of its quadrivalent influenza modified RNA (modRNA) vaccine in comparison to a conventional quadrivalent influenza vaccine. This double-blind study aims to recruit between 1,500 to 2,000 participants who are above 65 years of age within the country.
Context of Global Trial and Regulatory Setbacks
This milestone follows an earlier setback when Pfizer’s application to conduct a portion of the global trial in Brazil was rejected last month. Despite this, the company is moving forward with its clinical trial plans in Argentina, demonstrating its commitment to advancing the development of the next-generation influenza vaccine.
Competition in RNA-Based Therapeutics
Pfizer’s efforts in developing an advanced influenza vaccine come amidst competition with Moderna (NASDAQ: MRNA), a leading company in RNA-based therapeutics that is also developing a similar immunization. The race to bring an effective modRNA vaccine to market is intensifying, with both companies leveraging their expertise in RNA technology to address the significant public health need for improved influenza vaccines.-Fineline Info & Tech
